Clinical Trials Programs Therapy 
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT SANTÉ CANNABIS.
Cannabis Law Report
JULY 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
JULY 18, 2023
The Grant Program Details The heart of this landmark legislation lies in the development of a robust grant program. Notably, the grant program will target three prevalent and often debilitating conditions in military personnel: PTSD, traumatic brain injury (TBI) , and chronic traumatic encephalopathy (CTE).
Cannabis Law Report
AUGUST 7, 2021
MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023.
Veriheal
JUNE 29, 2021
In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. The FDA refers to this program as the expanded access program on their website. Cannabinoid Therapies for Cancer Patients.
Cannabis Law Report
MAY 19, 2022
This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.
Cannabis Law Report
SEPTEMBER 2, 2022
The clinical trial involving the use of Filament’s psilocybin received approval from Health Canada and was conducted as part of ATMA Journey Centre’s psychedelic-assisted therapist training program. was the first Canadian private company to engage in legally authorized psilocybin-assisted therapy.
Expert insights. Personalized for you.
104 
Let's personalize your content